Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Recruiting · NCT07225361 · Registry updated 2026-03-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 4 | 2026-03-17 | NCT07225361 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Northwestern University | 381 |
| TG Therapeutics, Inc. | 16 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern Memorial Hospital | Chicago | United States | 129 |